MarvelBiome

Let's start a conversation about the marvel of microbes.

MarvelBiome, Inc. is a biopharmaceutical company with a vision of harnessing the power of microbes for treating various human diseases.

MarvelBiome, Inc.'s privacy policy explains how it collects, uses, and protects information when people use its website and related pages or services.

Multiple biotech and pharma companies secure funding rounds for drug discovery and delivery platforms in the U.S. between October 16 and November 15, 2025. Investors include specialized venture capital firms and corporate partners supporting innovations in targeted therapies, gene editing, and advanced delivery systems. Notable deals span early-stage startups to established players in oncology, neurology, and rare diseases.

Dec 2025Castle Placement®News article

OpenEvidence secures $200 million in Series C venture funding led by GV, with participation from Coatue Management, Blackstone, BOND Capital, Thrive Capital, Sequoia Capital, Kleiner Perkins, and Craft Ventures. The round values the company at $5.8 billion pre-money. The funding follows continued growth in healthcare data analytics and evidence-based decision-making tools.

Oct 2025Silverwood PartnersNews article

Boston’s biotech firms raised over **$2.4 billion** in November, accounting for more than three-quarters of the region’s total venture capital funding. The influx included multiple newly launched companies, reinforcing the city’s dominance in life sciences investment. Tech startups also secured funding, though biotech remained the primary focus.

Dec 2020Boston Business JournalNews article